Morbidity and mortality of sickle cell disease in Côte d'Ivoire

Sickle cell anemia is a frequent constitutional disease with serious consequences. Despite the progress made in its management, morbidity and mortality. The aim of this study was to contribute to the study of morbidity and mortality in sickle cell disease in Côte d'Ivoire. retrospective, descriptive and analytical, bi-centric study based on 315 sickle cell patients followed from January 2011 to January 2021, selected according to a systematic random selection. The mortality rate was 15.2%, with acute severe anemia topped the list at 45.8%, followed by infections at 29.2%. The mean age was 18.44 years. Females predominated, with a sex ratio of 0.7. Access to treatment was difficult for 23%, and 86% of patients were uninsured. Clinically, 49.5% of patients had been hospitalized, and the main reason for hospitalization was vaso-occlusive crisis. (73%). 76.5% of subjects were not up to date with their vaccinations. 99% of patients had a treatment, including vasodilators 79.8% vasodilators and 68.9% folic acid. Follow-up was acceptable in 72.3% of cases. The incidence rate of complications was 26%, and the three groups anemic, infectious and ischemic complications, with a predominance of anemic complications at 45.1%. The incidence of complications and mortality remain high; the main causes are the same as those literature.